Table 2 Primary outcome (percentage of days the CPAP device was used for more than or equal to 4 h ≥ 70%) + the percentage of patients who use device ≥ 70% between active and placebo.

From: The efficiency of azelastine hydrochloride and fluticasone propionate nasal spray to improve PAP adherence in patients with obstructive sleep apnea

Variable

Intervention

(N = 59)

Placebo

(N = 57)

P value

Risk ratio+

%used day > 4 h ≥ 70%

22

17

0.40

1.25 (95% CI 0.74–2.10)

Back to article page